Media stories about Derma Sciences (NASDAQ:DSCI) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Derma Sciences earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned press coverage about the medical instruments supplier an impact score of 46.1432068235325 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

Shares of Derma Sciences (NASDAQ DSCI) remained flat at $$7.00 during midday trading on Wednesday. The company’s stock had a trading volume of 57,400 shares, compared to its average volume of 719,592. Derma Sciences has a 12 month low of $2.92 and a 12 month high of $7.05.

COPYRIGHT VIOLATION NOTICE: “Derma Sciences (DSCI) Receives Coverage Optimism Score of 0.15” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another site, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The correct version of this piece can be viewed at

About Derma Sciences

Derma Sciences, Inc (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection.

Insider Buying and Selling by Quarter for Derma Sciences (NASDAQ:DSCI)

Receive News & Stock Ratings for Derma Sciences Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Derma Sciences Inc and related stocks with our FREE daily email newsletter.